Assembly Biosciences announced that Phase 1b data for its helicase‑primase inhibitor candidates ABI‑5366 and ABI‑1179 will be presented at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich, Germany. The oral presentation for ABI‑5366 is scheduled for April 20, 2026, and the late‑breaker poster presentation for ABI‑1179 will take place on April 21, 2026.
The interim Phase 1b results released in December 2025 showed that ABI‑1179 achieved a 98 % reduction in HSV‑2 viral shedding and a 91 % reduction in virologically confirmed genital lesion rates, while ABI‑5366 demonstrated a 76 % reduction in shedding in a monthly dosing cohort. These encouraging data prompted Gilead Sciences to exercise its option to exclusively license the programs in December 2025, resulting in a $35 million upfront payment to Assembly Biosciences.
This presentation marks the first public disclosure of the latest clinical findings for the partnered genital‑herpes program. The data could influence Gilead’s decision‑making on further development, milestone payments, and potential commercialization, and it represents a potential first new treatment for recurrent genital herpes in more than 25 years.
Assembly Biosciences’ partnership with Gilead is a key component of its strategy. Gilead holds exclusive rights to develop, commercialize, and market the candidates, while Assembly stands to receive milestone payments and royalties. The upcoming ESCMID presentations therefore carry significant implications for Assembly’s future revenue streams and valuation, as successful data could accelerate Gilead’s development timeline and unlock additional milestone payments.
Chief Medical Officer Anuj Gaggar said, "The selection of ABI‑5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort." He added that the late‑breaker poster for ABI‑1179 highlights its potential as a long‑acting therapeutic option for patients with recurrent genital herpes.
Market reaction to the December 2025 option exercise was positive, with Gilead’s $35 million payment reflecting confidence in the clinical data and the unmet medical need in genital herpes. The announcement of the ESCMID presentations reinforces that confidence and signals a continued commitment to advancing the program.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.